Oculomotor Nerve Demyelination Secondary to Certolizumab Pegol

J Clin Rheumatol. 2018 Jun;24(4):234-236. doi: 10.1097/RHU.0000000000000688.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects
  • Arthritis, Psoriatic / drug therapy*
  • Certolizumab Pegol* / administration & dosage
  • Certolizumab Pegol* / adverse effects
  • Demyelinating Diseases* / chemically induced
  • Demyelinating Diseases* / diagnosis
  • Demyelinating Diseases* / physiopathology
  • Diagnosis, Differential
  • Glucocorticoids / administration & dosage
  • Humans
  • Male
  • Oculomotor Nerve Diseases* / chemically induced
  • Oculomotor Nerve Diseases* / diagnosis
  • Oculomotor Nerve Diseases* / physiopathology
  • Prednisone / administration & dosage*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Glucocorticoids
  • Tumor Necrosis Factor-alpha
  • Certolizumab Pegol
  • Prednisone